Advertisement

Topics

Patient recruitment completed in FITZROY Phase 2 Crohn's disease study with filgotinib

03:30 EDT 6 Aug 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
First selective JAK1 inhibitor in Phase 2 in Crohn's disease 175 patients randomized for 20 weeks of treatment Topline primary endpoint data expected in December 2015 Mechelen, Belgium; 6 August 2015 - Galapagos NV (Euronext & N...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Patient recruitment completed in FITZROY Phase 2 Crohn's disease study with filgotinib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system.  Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...